Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atherosclerosis
Drug-discovery company appoints new scientific advisory board
August 15th, 2005
Chronogen, Inc., a drug-discovery company developing therapeutics to treat oxidative stress and lipid disorders in age-related diseases, announced the appointment of a new scientific advisory board (SAB), significantly broadening the scope of expertise needed to bring the company to its next stages of development. These appointments include leading international experts in drug development to treat age-related diseases including diabetes complications, dyslipidemia, and atherosclerosis. These members join Prof. Siegfried Hekimi, PhD, (McGill University - Montreal, Quebec), CSO of Chronogen. Commenting on these appointments, Dr....
Source: Pharma Business Week (2005-08-15)
|
